Compare Stocks

→ The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KURA Kura Oncology	$18.75 +0.1%	$20.72	$7.41 ▼ $24.17	$1.43B	0.85	819,262 shs	816,007 shs
MDGL Madrigal Pharmaceuticals	$204.65 -6.3%	$244.64	$119.76 ▼ $322.67	$4.35B	-0.47	367,475 shs	575,483 shs
PMVP PMV Pharmaceuticals	$1.69 -6.6%	$1.69	$1.18 ▼ $9.72	$92.86M	1.65	507,210 shs	201,872 shs
VEGPF Vectura Group	$1.77	$1.77	$1.64 ▼ $2.74	$1.07B	0.37	2,185 shs	N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KURA Kura Oncology	+0.11%	+4.22%	-10.67%	+0.11%	+74.74%
MDGL Madrigal Pharmaceuticals	-6.29%	-10.37%	-17.35%	-11.09%	-30.81%
PMVP PMV Pharmaceuticals	-6.37%	+4.97%	-0.59%	-1.74%	-61.94%
VEGPF Vectura Group	0.00%	0.00%	0.00%	0.00%	0.00%

The "Smart Money" Is Ready for May 1st Are You? (Ad)

Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.

One Former Wall St. Trader Explains Why…

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KURA Kura Oncology	3.3391 of 5 stars	3.4	1.0	0.0	4.7	2.6	0.8	0.0
MDGL Madrigal Pharmaceuticals	4.6886 of 5 stars	4.4	1.0	0.0	4.6	3.1	4.2	0.6
PMVP PMV Pharmaceuticals	1.7488 of 5 stars	3.5	1.0	0.0	0.0	2.8	1.7	0.6
VEGPF Vectura Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KURA Kura Oncology	2.88	Moderate Buy	$28.28	50.81% Upside
MDGL Madrigal Pharmaceuticals	2.73	Moderate Buy	$356.73	74.31% Upside
PMVP PMV Pharmaceuticals	3.00	Buy	$5.67	235.31% Upside
VEGPF Vectura Group	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest MDGL, PMVP, KURA, and VEGPF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/22/2024	KURA Kura Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
4/22/2024	MDGL Madrigal Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform	$150.00
4/12/2024	PMVP PMV Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00
3/20/2024	MDGL Madrigal Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$325.00 ➝ $405.00
3/15/2024	MDGL Madrigal Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$405.00 ➝ $425.00
3/15/2024	MDGL Madrigal Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$338.00 ➝ $377.00
3/15/2024	MDGL Madrigal Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$320.00 ➝ $375.00
3/15/2024	MDGL Madrigal Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$351.00 ➝ $397.00
3/15/2024	MDGL Madrigal Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$382.00 ➝ $389.00
3/15/2024	MDGL Madrigal Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$349.00 ➝ $390.00
3/15/2024	MDGL Madrigal Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$337.00 ➝ $410.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KURA Kura Oncology	N/A	N/A	N/A	N/A	$5.35 per share	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	$20.53 per share	N/A
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	$4.41 per share	N/A
VEGPF Vectura Group	$244.76M	4.37	$0.28 per share	6.33	$1.16 per share	1.53

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KURA Kura Oncology	-$152.63M	-$2.08	N/A	N/A	N/A	N/A	-36.30%	-33.12%	5/8/2024 (Estimated)
MDGL Madrigal Pharmaceuticals	-$373.63M	-$19.94	N/A	N/A	N/A	N/A	-219.39%	-98.75%	5/7/2024 (Confirmed)
PMVP PMV Pharmaceuticals	-$68.96M	-$1.45	N/A	N/A	N/A	N/A	-30.27%	-27.33%	5/8/2024 (Estimated)
VEGPF Vectura Group	$157.16M	$0.26	6.81	17.70	N/A	N/A	N/A	N/A	N/A

Latest MDGL, PMVP, KURA, and VEGPF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2024	N/A	MDGL Madrigal Pharmaceuticals	-$6.06	N/A	+$6.06	N/A	N/A	N/A
2/29/2024	Q4 2023	PMVP PMV Pharmaceuticals	-$0.39	-$0.31	+$0.08	-$0.31	N/A	N/A
2/28/2024	Q4 2023	MDGL Madrigal Pharmaceuticals	-$5.26	-$5.68	-$0.42	-$5.68	N/A	N/A
2/27/2024	Q4 2023	KURA Kura Oncology	-$0.56	-$0.55	+$0.01	-$0.55	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VEGPF Vectura Group	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KURA Kura Oncology	0.02	12.26	12.26
MDGL Madrigal Pharmaceuticals	0.28	5.38	5.38
PMVP PMV Pharmaceuticals	N/A	14.78	14.78
VEGPF Vectura Group	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
KURA Kura Oncology	N/A
MDGL Madrigal Pharmaceuticals	98.50%
PMVP PMV Pharmaceuticals	90.20%
VEGPF Vectura Group	N/A

Insider Ownership

Company	Insider Ownership
KURA Kura Oncology	5.50%
MDGL Madrigal Pharmaceuticals	23.92%
PMVP PMV Pharmaceuticals	7.60%
VEGPF Vectura Group	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
KURA Kura Oncology	142	76.18 million	71.99 million	Optionable
MDGL Madrigal Pharmaceuticals	376	19.90 million	15.14 million	Optionable
PMVP PMV Pharmaceuticals	63	51.44 million	47.53 million	Optionable
VEGPF Vectura Group	502	604.26 million	N/A	Not Optionable

MDGL, PMVP, KURA, and VEGPF Headlines

Source	Headline
	Critical Review: Agios Pharmaceuticals (NASDAQ:AGIO) and Vectura Group (OTCMKTS:VEGPF) americanbankingnews.com - April 20 at 1:26 AM
	European Stocks See Mixed Session as U.K.'s FTSE Leads thestreet.com - January 16 at 11:20 PM
	VECTURA GROUP LS -,000271 (V4TA.BE) finance.yahoo.com - January 15 at 2:59 PM
	Vectura Group PLC (V4TA.BE) finance.yahoo.com - January 9 at 10:12 AM
	Results for 'Vectura-Fertin Pharma' afaqs.com - October 11 at 7:33 PM
	Vectura Group (OTC:VEGPF), Short Interest Report benzinga.com - July 18 at 11:14 PM
	Carlyle stays in race for Vectura uk.finance.yahoo.com - August 27 at 12:54 PM
	Form 8.3 - Form-8.3 - VECTURA GROUP PLC - 20210826 finance.yahoo.com - August 27 at 6:38 AM
	Philip Morris chief attacks critics as Vectura bid tests investors uk.finance.yahoo.com - August 20 at 2:24 AM
	Markets: FTSE inches to new post-pandemic high as Vectura takeover draws closer uk.finance.yahoo.com - August 13 at 4:18 AM
	Vectura auction called off after Carlyle declines to beat Philip Morris bid uk.finance.yahoo.com - August 10 at 3:02 PM
	UPDATE 1-Vectura takeover battle could slip into auction - UK regulator finance.yahoo.com - August 9 at 8:04 AM
	Philip Morris, Carlyle could fight it out for UK's Vectura in auction ring ca.finance.yahoo.com - August 9 at 8:04 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Kura Oncology

NASDAQ:KURA

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Madrigal Pharmaceuticals

NASDAQ:MDGL

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

PMV Pharmaceuticals

NASDAQ:PMVP

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Vectura Group

OTCMKTS:VEGPF

Vectura Group Plc engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial